Lakefront Biotherapeutics (LKFT) Liabilities from Discontinued Operations (2020 - 2023)
Lakefront Biotherapeutics (LKFT) posted quarterly Liabilities from Discontinued Operations of 36464606.67 for Q4 2023, up 269.21% on a QoQ basis from 9876305.12 in Q1 2023.
Lakefront Biotherapeutics (LKFT) Liabilities from Discontinued Operations (2020 - 2023) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 36464606.67 the latest figure, recorded in Q4 2023.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 36464606.67 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 36464606.67 (changed N/A YoY) and the FY2023 annual result came in at 36464606.67, changed N/A from the prior year.
- Liabilities from Discontinued Operations rose to 36464606.67 in Q4 2023 per LKFT's latest filing, from 9876305.12 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for LKFT reached as high as 36464606.67 in Q4 2023 and fell as low as 9876305.12 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 36.46 Mn |
| Dec 31, 2023 | 36.46 Mn |
| Mar 31, 2023 | 9.88 Mn |
| Mar 31, 2023 | 9.88 Mn |
| Dec 31, 2020 | 10.15 Mn |
| Dec 31, 2020 | 10.15 Mn |